Latest Breaking News On - International publication no - Page 1 : vimarsana.com

Reviewing Federal Circuit Obviousness Proceedings for Spring 2024

Janssen v. Teva: Not an April Fool's Day Joke for Life Sciences Companies | Goodwin

Pacific Biosciences of California, Inc. v. Personal Genomics Taiwan, Inc. (Fed. Cir. 2024) | McDonnell Boehnen Hulbert & Berghoff LLP

The importance of claim construction, and how construing the same term facing a challenge based on different prior art in separate inter partes review proceedings can result in contrary...

In re Theripion (Fed. Cir. 2023) | McDonnell Boehnen Hulbert & Berghoff LLP

The Patent Trial and Appeal Board (PTAB) has benefited, particularly after enactment of the Leahy-Smith America Invents Act, from the deference to its factual findings mandated by the...

Tonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune Conditions

Home / Top News / Tonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune Conditions Tonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune Conditions GMP Production of TNX-1500 is Expected to be Available in the Third Quarter of 2021 CHATHAM, N.J., Jan. 14, 2021 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the World Intellectual Property Organization has published a patent application filed under the Patent Cooperation Treaty covering TNX-1500, a humanized monoclonal antibody (mAb) directed against CD40-ligand, which is also known as CD154, T-BAM, 5c8 antigen, TRAP and gp39. The patent application is titled “Anti-CD154 Antibodies and Uses Thereof” and published under International Publication No. WO 2021/001458 A1. If claims are granted, a patent issuing from a national stage of this application could potentially provide U.S. patent coverage for the TNX-1500 composition of matter through 2040 excluding possible patent term extensions or patent term adjustments.

American Manganese Inc.: Journal of the Electrochemical Society Publishes Paper Describing American Manganese's Patented Lithium-ion Battery Cathode Recycling Process

American Manganese Inc.: Journal of the Electrochemical Society Publishes Paper Describing American Manganese's Patented Lithium-ion Battery Cathode Recycling Process SURREY, BC / ACCESSWIRE / January 6, 2021 / American Manganese Inc. (TSXV:AMY)(OTC PINK:AMYZF)(FRA:2AM) (" AMY" or the " Company") is pleased to announce that the detailed technical paper, 'Experimental Study on Recycling of Spent Lithium-Ion Battery Cathode Materials' has been submitted, reviewed, and published in the Journal of the Electrochemical Society (JES). The JES is a peer-reviewed journal established in 1902 and is one of the most highly cited journals in electrochemistry and solid state science and technology. The abstract can be viewed in the following link: Experimental Study on Recycling of Spent Lithium-Ion Battery Cathode Materials - IOPscience.